Jeffrey Engelman, MD, PhD

Name: Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
Start: 2025-09-07T18:30:00+02:00
End: 2025-09-07T19:30:00+02:00

September 1, 2016

|

By

|

Estimated Read Time:

1 minute

Names & News

Jeffrey Engelman has been appointed Vice President and Global Head of Oncology at the Novartis Institutes of BioMedical Research. Prior to joining Novartis, Dr. Engelman was Director of the Center for Thoracic Oncology and Molecular Therapeutics at Massachusetts General Hospital, Boston, US, and Harvard Medical School professor.

About the Authors

Share this Article:

Jeffrey Engelman, MD, PhD

Recent Posts

World Conference Conversations: Inside WCLC 2025

Opening Plenary to Highlight Significant Achievements in Thoracic Oncology

Third Annual Amazing Case Race Returns for WCLC 2025

Preconference Workshops Offer Diverse Educational Opportunities Across Specialties

IS03: Satellite EBAC/CME Symposium by Answers in CME: Reshaping the Management of Metastatic NSCLC: Tackling HER2 Overexpression to Elevate Outcomes

Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC